Lung Cancer Trials Ask AI to find trials
WithdrawnPhase 2NCT01184287
Official study title

A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer

Study summary

The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRanpirnase

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 2, 2015 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?6 U.S. locations

Locations may change over time.

Who runs it?Tamir Biotechnology, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Tamir Biotechnology, Inc.
Interventions being studied
Drug: Ranpirnase
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age greater than 18 years
  • ECOG less than 2
  • Estimated survival of greater than 12 weeks
Reasons someone may not be able to joinExclusion criteria
  • Prior systemic chemotherapy for locally advanced or metastatic NSCLC
  • Use of any investigational agent within 28 days prior to registration
  • Known hypersensitivity to any of the study drugs
  • Brain metastases or leptomeningeal disease
  • History of prior malignancy within the past three years

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Tower Cancer Research FoundationBeverly Hills, California
  • Van Andel Research InstituteGrand Rapids, Michigan
  • Sletten Cancer SpecialistsGreat Falls, Montana
  • The Cancer Institute at NYU Langone Medical CenterNew York, New York
  • Tri-county Hematology-Oncology Associates, IncCanton, Ohio
  • Northern Utah AssociatesOgden, Utah

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 2, 2015. Always confirm current availability with the study team.

View original record ↗